Long-term nationwide trends in the treatment of and outcomes among pancreatic cancer patients.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
05 2022
Historique:
received: 31 05 2021
revised: 09 11 2021
accepted: 15 11 2021
pubmed: 1 12 2021
medline: 12 5 2022
entrez: 30 11 2021
Statut: ppublish

Résumé

Whilst treatment modalities for pancreatic cancer patients have evolved in recent years, their impact on outcomes remains relatively unexamined on a national scale. We aimed to analyse changes in overall survival and trends in surgical and oncological treatments in pancreatic cancer patients diagnosed in the periods 2000 through 2008 and 2009 through 2016 in Finland. We collected data for pancreatic cancer patients diagnosed between 2000 and 2016, gathering data from the Finnish national registries on surgeries, oncological treatments and time of death. Follow-up continued through the end of 2018. We compared patients diagnosed between 2000 and 2008 to those diagnosed between 2009 through 2016. Our study comprised 14 712 pancreatic cancer patients. There was no significant change in the national resection rate (8.1% vs 8.0%, p = 0.690). In radical surgery patients, median survival improved from 20 months (95% confidence interval (CI) 18-22) to 28 months (CI 25-31) (p < 0.001), with 1-year survival ranging from 70% to 81%. In the no-surgery group, median survival slightly improved from 3.1 months (CI 3.0-3.3) to 3.3 months (CI 3.1-3.4) (p < 0.001). The proportion of radical surgery patients receiving preoperative oncological treatment increased from 4% to 13% (p < 0.001) and only postoperative treatment from 25% to 47% (p < 0.001). Whilst the resection rate did not increase, the prognosis of pancreatic cancer patients improved, particularly amongst radical surgery patients resulting most likely from the fact that a larger proportion of patients receive more effective oncological treatments.

Identifiants

pubmed: 34844817
pii: S0748-7983(21)00925-2
doi: 10.1016/j.ejso.2021.11.116
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1087-1092

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Panu Aaltonen (P)

Department of Surgery, Translational Cancer Medicine Research Programme, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address: panu.aaltonen@hus.fi.

Olli Carpén (O)

Medicum, Research Programme in Systems Oncology and HUSLAB, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address: olli.carpen@helsinki.fi.

Harri Mustonen (H)

Department of Surgery, Translational Cancer Medicine Research Programme, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address: harri.mustonen@helsinki.fi.

Pauli Puolakkainen (P)

Department of Surgery, Translational Cancer Medicine Research Programme, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address: pauli.puolakkainen@hus.fi.

Caj Haglund (C)

Department of Surgery, Translational Cancer Medicine Research Programme, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address: caj.haglund@hus.fi.

Katriina Peltola (K)

Comprehensive Cancer Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address: katriina.peltola@hus.fi.

Hanna Seppänen (H)

Department of Surgery, Translational Cancer Medicine Research Programme, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address: hanna.seppanen@hus.fi.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH